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PREOPERATIVE 
ACCELERATED 
RADIOTHERAPY AND 
CHEMOTHERAPY IN 
STAGE lilA (N2) 
NON-SMALL-CELL LUNG 
CANCER 
Forty patients with N2 non-small-cell lung cancer (stage IIIA), as deter- 
mined by mediastinoscopy, were entered into a preoperative neoadjuvant 
study of chemotherapy (platinum, 5-fluorouracil, vinblastine) and acceler- 
ated radiotherapy (150 cGy twice per day for 7 days) for two cycles. Surgical 
resection was then performed and followed up with an additional cycle of 
chemotherapy and radiotherapy. All patients completed preoperative ther- 
apy. A major clinical response was seen in 87% of patients. Thirty-five 
patients underwent resection (one preoperative death, one refused opera- 
tion, one had deterioration of pulmonary function, and two had pleural 
metastases). Operative mortality rate was 5.7% (2/35). Sixty percent of 
patients had no complications. Major complications included pulmonary 
emboli (three), pneumonia (two), and myocardial infarction (one). Down- 
staging was seen in 46% of patients, with two patients (5.7%) having no 
evidence of tumor in the specimen, five patients having sterilization of all 
lymph nodes, and nine patients having sterilization of mediastinal nodes 
but positive N1 nodes. Median survival of 40 patients was 28 months, with 
a projected 5-year survival of 43%. Patients with downstaged disease had 
statistically significant improved survival compared with patients whose 
disease was not downstaged. (J THORAC CARDIOVASC SURG 1996;111:123-33) 
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T he incidence of lung cancer continues to increase, especially among women. The number of new 
cases in 1995 is estimated to be 96,000 among men 
and 73,000 among women. 1 Lung cancer is the 
leading cause of cancer deaths among both men and 
women, accounting for an estimated 95,400 deaths 
among men and 62,000 among women. 
Despite the enormity of the problem and the atten- 
tion it has generated, little progress has been made in
improving overall. The most recent edition of Cancer 
Statistics for 1995 reveals that the overall survival for 
lung cancer is still only 14% among whites and 11% 
among blacks , compared with 8% and 5%, respec- 
tively, in 1960. Although this is a statistically significant 
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increase, innovative treatment s rategies are needed to 
improve even further the overall survival of this dev- 
astating cancer. It is estimated that bout 43% of 
patients are initially seen with localized (15%) or 
regional (28%) disease, making this group the most 
likely target for further investigation. 
Recent years have seen great improvements in
surgical techniques to allow sleeve lobectomy, cari- 
nal resections, and other radical operations to be 
performed. These improvements have benefited a 
small number of patients. Progress in postoperative 
care and lung-sparing techniques have expanded the 
possibilities for high-risk patients and contributed to 
decreased postoperative morbidity and mortality 
rates. Unfortunately, these advancements are suit- 
able only for a small percentage of the patients with 
lung cancer. Operation is accepted as the best 
therapy for stage I and II lung cancer, achieving cure 
rates between 40% and 80%. The results for more 
advanced local regional ung cancer have not been 
as good with operation alone. The current staging 
system for lung cancer has identified a subgroup of 
patients with a potentially more favorable prognosis. 
These patients have disease classified as stage IIIA, 
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which includes lung cancer invading the chest wall, 
superior sulcus tumors, and certain cases of affected 
ipsilateral mediastinal lymph nodes. 
The group of patients with affected ipsilateral 
mediastinal lymph nodes represents a challenge and 
a possibility to improve the overall results. It is 
estimated that approximately 25% to 30% of pa- 
tients with potentially operable lung cancer have 
affected mediastinal lymph nodes. 2' 3 A small subset 
of patients has been identified as having potentially 
favorable outcome--those with single tracheobron- 
chial, intranodal metastases. This unfortunately sit- 
uation represents only about 10% of the group with 
affected mediastinal nodes. If these nodes are found 
before operation by mediastinoscopy and treated 
with surgical resection and postoperative irradia- 
tion, the 5-year survival is approximately 10%. 2 If 
these nodes are found at the time of thoracotomy, 
after negative results of mediastinoscopy, and treated 
with resection and postoperative irradiation, the 5-year 
survival is about 30%. z' 3 Even in this most favorable 
group, long-term survival is lower than desired, and 
the remaining 90% of patients with affected mediasti- 
nal nodes not in this favorable subset have an expected 
survival less than 10%. Because of the large number of 
patients, the poor results, and the possibility of affect- 
ing the overall prognosis of lung cancer, it is important 
to develop effective treatment strategies to deal with 
this group of patients. 
Multimodality therapy of lung cancer has many 
theoretic advantages. Certain chemotherapeutic 
agents and radiotherapy have synergistic effects. The 
ability of certain chemotherapeutic agents to act as 
radiosensitizers may enhance the local control of 
tumors. If the chemotherapeutic agents are active 
against he neoplasms, they may be able to control 
micrometastatic disease that may be undectable at 
the time of presentation. There are also theoretic 
disadvantages, but in light of the poor outlook of 
this group of patients, the potential advantages seem 
to outweigh any negatives. 
There is a growing body of data regarding the 
multimodality neoadjuvant approach to stage I I IA  
lung cancer. 4-1° To date, the optimal regimen has yet 
to be defined. Questions remain regarding whether 
chemotherapy is better alone or in combination with 
radiotherapy. Concern has been raised regarding 
the increased morbidity of preoperative radiother- 
apy in conjunction with chemotherapy. In an at- 
tempt to add to the body of knowledge regarding 
neoadjuvant therapy for stage I I IA  lung cancer, as 
defined by mediastinoscopy-proven affected medias- 
tinal nodes, we entered patients prospectively into a 
phase II preoperative trial of accelerated radiother- 
apy and chemotherapy. 
Patients and methods 
Eligibility. A ¢onsecutive group of patients with medi- 
astinoscopy-proven affected ipsilateral mediastinal lymph 
nodes Were eligible for the protocol (Tl to T3 N2). All 
patients had histologically proven non-small-cell ung 
cancer (NSCLC) (bronchoalveolar carcinoma was exclud- 
ed). All patients were judged to have adequate lung 
function to undergo surgical res{tion, with predicted 
postoperative forced expiratory volume in 1 s«ond 
(FEV1) greater than 800 mL All patients had negative 
results of bone scans, brain scans, and liver scans and were 
found to have normal adrenal glands by computed tomog- 
raphy. Patients were ex¢luded if previous malignancy 
existed. Patients were required to have a granulocyte 
count greater than 1800 cells//zl, platelet count greate 
than 100,000 cells/~L1, hemoglobin level greater than 10 
gin/dl, blood urea nitrogen less than one fifth of normal 
values, bilirubin level less than 1.5 mg/dl, creatinine level 
less than 1.5 mg/dl, or creatinine clearance greater than 60 
tal/min. Informed consent was obtained from all patients. 
Treatment plan 
Accelerated radiotherapy. A preoperative dose of 4200 
cGy was delivered in two separate sessions by an acceler- 
ated schedule. The first session delivered 2100 cGy in 150 
cGy fractions, twice daily with an intertreatment i erval 
of 5 to 7 hours, 5 days a week for i week, starting on day 
1. The second session delivered an additional dose of 2100 
cGy in the same way, starting day 19 after a resting period 
of 10 days after the first session to avoid excessive 
dysphagia from anticipated esophagitis. 
Chernotherapy. All patients received chemotherapy with 
5-fluorouracil, vinblastine, and cisplatin, of which two cycles 
were given beginning on days 1 and 29. Doses were as 
follows: 5-fluorouracil at 30 mg • kg -1 • day -1 by 72-hour 
continuous infusion beginning day 1 of each cycle, cisplatin 
at 100 mg/m 2given 2 to O hours after initiation 5-fluorouracil 
and administered over a 30-minute period, and intravenous 
vinblastine as a 4 mg • m -2 • day -1 bolus given on day 1. 
From 1 to 2 hours before cisplatin was given, 1 L of 5% 
dextrose in water and 0.5N saline solution with 8 meq 
magnesium sulfate was given. Immediately before cisplatin, 
2.5 gm of mannitol was given intravenously over 10 minutes. 
Once cisplatin was given, 500 ml of 5% dextrose in water and 
0.5N saline solution with 10 meq potassium chloride, 8 meq 
magnesium sulfate, and 12.5 gm of mannitol was given over 
a 2-hour period with replacement of urine output with an 
equal volume of 5% dextrose in water and 0.5N saline 
solution over a 24-hour period. 
Operation. All patients underwent restaging of disease 
before surgical resection. Surgical resection, designed to 
take place on day 57, encompassed all known tumor at the 
time of operation and included mediastinal lymph hode 
dissection in all patients. Because of the potential for 
bronchial stump complications, pecial precautions were 
taken to cover the bronchial stump with pedicled tissue 
flaps (intercostal muscle, pericardial fat pad, or even 
omentum in some cases). Each patient was given prophy- 
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laxis against deep venous thrombosis consisting of 5000 
units of subcutaneous heparin before operation and twice 
daily after operation until that patient was fully ambula- 
tory. Compression boots were placed before operation 
and continued after operation until the patient was fully 
ambulatory. 
Additional therapy. After thoracotomy on day 85, all 
patients were to receive an additional 1800 cGy in 150 cGy 
fractions, twice daily with an intertreatment i erval of 5 
to 7 hours, 5 days a week for 6 treatment days. A third 
cycle of chemotherapy aspreviously described was also 
given on day 85. 
All patients were monitored for toxic effects from chemo- 
therapy and radiation therapy. Adjustments in doses and 
treatment intervals were made accordingly. Patients were 
monitored for tolerance to treatments, complications, ability 
to complete all treatments, urgical results, and survival. 
Response to treatment was categorized as complete disap- 
pearance of all measurable disease, as determined by radio- 
graphic examination. Partial response was determined when 
a reduction of greater than 50% compared with pretreat- 
ment measurements in the sum of the perpendicular diam- 
eters of measurable disease was observed. Regression was 
determined by a decrease inmeasurements agreed on by two 
independent investigators. Stable disease was determined by 
observation of a reduction of less than 50% or up to a 25% 
increase in measurements compared with pretreatment mea- 
surements. 
Any patienlL with rapid progression of disease during 
treatment was removed from the protocol. If at any time 
the constraints of this protocol were determined to be 
detrimental toa patient's health, that patient was removed 
from the protocol. 
Statisties. The survival curves were calculated by the 
Kaplan-Meier method. 11 The log-rank test was used to 
compare survival among subgroups. Follow-up data were 
obtained from direct patient contact, office records, or 
referring doctor's offices. 
Results 
Patient demographics. From January 1988 to 
December 1994, 40 patients were entered into the 
protocol. There were 26 male and 14 female pa- 
tients. The mean age of the men was 56.4 years; 
mean age! was 61 years for the women. The perfor- 
mance status of all patients was judged to be 0 or 1 
(Karnovsky). The average FEV 1 of the 40 patients 
was 2.56 E (1.3 to 4.1 L). All patients had histologic 
proof by mediastinoscopy of NSCLC metastatic to 
mediastinal nodes. All but one patient had either 
ipsilateral paratracheal, tracheobronchial, or subcari- 
nal nodes found to be affected by metastatic carcinoma 
(stage IIIA). The one patient entered into the study 
whose disCase was technically IIIB was entered on the 
basis of an affected left tracheobronchial node and a 
i 
primary lung cancer involving the carina. It was con- 
sidered reasonable to include this patient because the 
left tracheobronchial node was in proximity to the 
Table I. TNM status before and after operation 
Status No. of patients 
Before operation 
T1N2 
T2N2 
T3N2 
T4N3 
After operation, downstaged 
TON0 
TIN0 
T1N1 
T2N1 
After operation, unchanged 
T1N2 
T2N2 
T3N2 
10 
24 
5 
1 
primary lesion and would be removed en bloc fashion 
with the carinal pneumonectomy. 
All patients completed preoperative radiother- 
apy. No patients were removed from the protocol 
because of toxic effects. One patient died at home 
after completion of chemoradiotherapy. One pa- 
tient sustained an asystolic arrest at surgical explo- 
ration, was subsequently judged to have insu#icient 
pulmonary reserve to withstand a bilobectomy, and 
underwent consolidative radiotherapy. Two patients 
were found to have pleural metastases before surgi- 
cal resection and therefore did not undergo resec- 
tion. The remaining 35 patients underwent surgical 
resection with curative intent. Of the 35 patients 
undergoing surgical resection, 32 received a third 
cycle of chemotherapy. Thirty-four of the 35 pa- 
tients undergoing surgical resection received post- 
operative irradiation. 
Histology. According to the final pathologic speci- 
men, adenocarcinoma w s the diagnosis in 25 patients 
and squamous cell carcinoma was the diagnosis in 15 
patients. Adenocarcinoma was present in 15 men and 
squamous carcinoma was present in the remaining 11. 
Adenocarcinoma was present in 10 women and squa- 
mous carcinoma was present in the remaining four. 
Nodal status. Single nodes only were affected in 
27 patients (right paratracheal in nine, left tracheo- 
bronchial in seven, subaortic in six, subcarinal in 
four, and right tracheobronchial in one). Thirteen 
patients were found to have multiple positive nodes 
at the time of mediastinoscopy (right paratracheal 
and subcarinal in nine, right tracheobronchial nd 
right paratracheal in three, and left tracheobron- 
chial and subcarinal in one). The preoperative TNM 
statuses are shown in Table I. 
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Table II. Operations performed on 35 patients 
Procedure No. of patients 
Right upper lobectomy 
Sleeve right upper lobectomy 
Right pneumonectomy 
Right carinal pneumonectomy 
Right upper and middle lobectomy 
Right upper lobe and chest wall 
Right lower and middle lobectomy 
Left upper lobectomy 
Left pneumonectomy 
Left upper lobe and chest wall 
Left lower lobectomy 
Response to treatment. Treatment toxic effects 
were manageable in all patients. Moderate dyspha- 
gia and leukopenia were noted in 50% of patients. 
There were no deaths directly related to preopera- 
tive treatment. The single death before surgical 
resection was from a presumed pulmonary embolus 
after completion of preoperative treatments. This 
patient died at home and no post mortem examina- 
tion was done. All patients had pathologic evidence 
of response to treatment, either by downstaging of
disease or the presence of necrosis in the final 
specimen submitted for pathologic examination. 
Major clinical response (>50% reduction in tumor 
volume) was obtained in 87.5% of patients (35/40). 
Operations. Thirty-five patients underwent re- 
section of the primary tumor and mediastinal node 
dissection. All patients were judged to have com- 
plete resection at the time of operation on basis of 
the surgeon's judgment and results of intraoperative 
frozen-section examination. The operations are 
listed in Table II. This group is notable for the six 
sleeve right upper lobectomies and two carinal 
resections. The bronchial stump was covered with a 
viable pedicle of tissue in all patients. The pericar- 
dial fat pad was used in 15, a pedicled intercostal 
muscle was used in 14, omentum was used in four 
patients early in the experience, and pleura alone 
was used in two patients. 
Resectability. As stated previously, 35 of the 40 
patients underwent surgical resection (87.5%). All 
35 patients who underwent resection (100%) were 
considered to have complete resections on the basis 
of the surgeon's judgment and results of intraoper- 
ative frozen-section examination. On final review, 
however, four patients had a change in interpreta- 
tion, with affected margins being found on review of 
frozen sections in two cases and unsampled margins 
being called positive in two cases (88.5% complete 
resections among those undergoing resection 
[31/35] and 77.5% among the entire protocol cohort 
[31/40]). 
Mortality. There were three treatment-related 
deaths (7.5%). One 63-year-old woman who had 
completed her preoperative therapy died before 
operation. She died at home of a presumed pulmo- 
nary embolus. No post mortem examination was 
performed. There were two postoperative deaths 
(5.7%). One patient died of pneumonia 1 month 
after operation. This patient had a preoperative 
FEV1 of 2.43 and had undergone a left upper 
lobectomy and chest wall resection. The second 
patient died of an arrhythmia nd pulmonary em- 
bolus after a right upper lobectomy and chest wall 
resection. Preoperative FEV1 was 2.02. Both pa- 
tients who died after operation had dramatic re- 
sponses to therapy, with no viable tumor anywhere 
in one patient and 90% radiation effect and negative 
lymph nodes in the other patient. 
Morbidity. Twenty-one patients of the 35 under- 
going resection had no postoperative complications 
(60%). A prolonged air leak (>7 days) and atrial 
fibrillation each occurred in five patients. There 
were three documented pulmonary emboli, one of 
which was fatal. Two patients had documented 
pneumonia, one case of which was fatal. There was 
a single instance ach of gastrointestinal bleeding 
and myocardial infarction. One patient sustained an 
intraoperative asystolic arrest as a result of a con- 
tralateral tension pneumothorax t the institution of 
one-lung ventilation. This patient was successfully 
resuscitated but never was operated on because of 
diminished pulmonary reserve. One patient was 
found to have a completely atelectatic lung after 
postoperative radiation therapy was completed. This 
patient had previously undergone a sleeve right 
upper lobectomy and omental wrap. A delayed 
separation of the bronchus was diagnosed, necessi- 
tating completion pneumonectomy. The patient 
made an uneventful recovery from this operation. 
Postoperative pathologic findings. Two of 35 pa- 
tients (6%) were judged to have no evidence of 
tumor in their specimens. Five additional patients 
had no evidence of tumor in any examined lymph 
nodes but did have evidence of residual tumor in the 
primary site. Nine patients had residual tumor in the 
primary site with only N1 nodes having evidence of 
tumor. Sixteen patients overall had sterilization of 
previously affected mediastinal lymph nodes (46%). 
Twenty percent (7/35) had all nodes sterilized. The 
overall incidence of downstaging was 46% among 
The Journa l  o f  Thorac ic  and  
Card iovascu lar  Surgery  
Vo lume 111,  Number  1 
Mathisen et al. 1 2 7 
100 
90- 
80-- 
7O 
60 
50- 
40- 
30 
20 
10 
0 
0 
%_ 
ù , ~ i ~ 4 , , i , , ~ , i , , , , i , , , , i , , , ~ i , , , ~ i , , , , t , ~ , , i 
10 20 30 40 50 60 70 80 90 
Months 
Fig. 1. Overall survival (n = 40). 
patients who underwent resection (Table I). Fifty- 
four percent of all patients who underwent resection 
still had microscopic evidence of disease in medias- 
tinal lymph nodes or showed essentially no change 
in overall stage of disease. The one patient judged to 
have stage IIIB disease on the basis of carinal 
involvement and a positive left tracheobronchial 
node was judged after operation to have T1 NO 
status, with no tumor seen in lymph nodes and only 
a 4 mm residual tumor in the right main bronchus. 
Survival. Follow-up has ranged from 4 months to 
83 months. The median overall survival of the 40 
patients was 28 + 1.98 months (Fig. 1). The median 
overall survival of the 35 patients undergoing resec- 
tion was 37 + 1.74 months. The median survival of 
the patients whose disease was downstaged by pre- 
operative i chemotherapy and radiotherapy has not 
yet been reached, with 11 of 16 patients till alive. 
The median survival of those with disease that was 
not downstaged was 26 _-L- 1.1 months. Eight of 19 
patients whose disease was not downstaged remain 
alive. The'! survival of the patients with downstaged 
disease Was greater than that of those patients 
whose disease was not downstaged, and this repre- 
sents a significant statistical difference (p = 0.04; 
Fig. 2). Analysis of the survival for patients with 
single hode involvement compared with those with 
multiple node involvement showed no statistical 
difference between the two groups, but a trend 
toward better long-term survival among patients 
with only single node involvement ws apparent (Fig. 
3). Local-regional tumor control has been judged to 
be effective in 85% of patients (34/40). 
Discussion 
The goals of this phase II study were to determine 
the feasibility of this multimodal approach to the 
treatment of patients with histologically proven 
stage IIIA disease, toxic effects of therapy, response 
to therapy, resectability rate, postoperative morbid- 
ity and m0rtality rates, and survival. The study 
results were judged to be favorable on all accounts. 
All patients who were entered into the protocol 
completed the preoperative phase of the study. 
Although moderate dysphagia or leukopenia oc- 
curred in 50% of patients, there were no deaths 
directly related to the treatment. Noncompliance 
was a factor in only one patient, who chose to delay 
operation because of fatigue. By the time this pa- 
tient agreed to operation (4-month delay), meta- 
static disease was evident. A major clinical response 
(>50% reduction) was noted in 87.5% of patients. 
Two patients were found to have pleural metas- 
tases (one before operation and one at exploration) 
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Fig. 3. Survival of patients with single (bold line) versus multiple (narrow Iine) affected nodes. 
and did not undergo resection of the primary tumor. 
Thoracoscopy at the time of initial presentation 
might have detected this problem in these two 
patients and should be considered in the future to 
accurately assess patients with advanced stage dis- 
ease before their entry into neoadjuvant protocols. 
The ability of preoperative r gimens to downstage 
disease has been demonstrated byothers .  4-1° Of the 
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35 evaluable patients, only two patients had no 
evidence of disease in the entire specimen (6%), 
which is lower than the 20% figure others have 
reported (Table III). 60ur  previous experience with 
standard, daily radiotherapy and similar chemother- 
apy achieved a 16% rate of no evidence of disease in 
the resected specimen, s Downstaging by result of 
sterilization of mediastinal nodes in this study was 
achieved in 46% of the 35 patients who underwent 
resection, with complete sterilization of all lymph 
nodes in 20% of patients (7/35). The ability of 
neoadjuvant therapy to sterilize the mediastinum is 
an important aspect of this form of therapy and 
possibly has even greater implications in some pa- 
tients with stage IIIB disease. 9 
The resectability rate in this group of patients has 
been excellent (Table IV). Of the 40 patients en- 
tered into this study, 35 underwent what was 
thought o be a curative resection (87.5%). Of the 
five patients who did not undergo resection, two 
might have been eliminated from the protocol in the 
beginning ;had thoracoscopy been done and detected 
their pleural metastases. One patient had a resect- 
able lesion, but intraoperative anesthetic airway 
complications developed and the operation had to 
be stoppe d. One patient with a potentially resect- 
able lesion delayed operation for 4 months and was 
then found to have metastatic disease. All 35 pa- 
tients underwent resection presumed to be curative 
on the basis of intraoperative frozen sections and 
the surgeon's judgment. Four patients were classi- 
fied in the final pathology report as having positive 
resection margins. Therefore, 31 of 35 resections 
(88.6%) were complete, and 31 of the original group 
of 40 patients (77.5 %) had complete resections. This 
resectability rate is as good or better than that seen 
in most 0ther series 4-1° and is better than our 
previous experience with another preoperative r g- 
imen s (Table IV). 
The overall morbidity and mortality rates were 
quite acceptable. There were three deaths among 
the 40 patients entered into the protocol (one 
before and two after operation). The operative 
mortality rate of 5.7% is comparable to the other 
reports in the literature. 4-1° Both postoperative 
deaths appeared to be unrelated to the preoperative 
therapy. Morbidity was a concern because of the 
preoperative therapy and the planned postoperative 
therapy. Most surgeons elected to cover the bron- 
chial stump with pedicled viable tissue to reduce the 
risk of po~toperative bronchopleural fistula. There 
were no bronchopleural fistulas despite the use of 
Table III. Response rates to various neoadjuvant 
programs 
Smdy No. of patients NED (%) % Downstaged 
MSKCC 136 17 21 
CALGB 8935 74 - -  22 (10/46) 
RUSH 128 22 (22/94) - -  
MGH* 40 6 (2/35) 46 (i6/35) 
MSKCC, Memorial Sloan Kettering Cancer Center; ALGB 8935, Cancer 
and Leukemia Group B; RUSH,, Rush-Presbyterian-St. Luke's; MG[I, 
Massachusetts General Hospital; NED, no evidence of disease. 
*This sttldy. 
preoperative and postoperative radiation and bron- 
choplastic procedures in eight patients. The single 
patient requiring a completion pneumonectomy had 
undergone a sleeve right upper lobectomy wrapped 
with pedicled omentum. After completion of the 
planned postoperative radiotherapy, the patient was 
found to have a totally atelectatic lung occluded by 
omentum. The two ends of the bronchial anastomo- 
sis were found to have separated, and completion 
pneumonectomy was required. Whether the prob- 
lem was a technical problem or caused by the 
radiotherapy is unclear, but it is clear that the 
omentum prevented a catastrophic omplication. 
Twenty-one of the 35 patients who underwent re- 
section had no postoperative complications. None of 
the postoperative complications were considered 
directly related to the preoperative therapy. 
There is a spectrum of disease that is classified as 
N2. The most favorable outcomes occur among 
patients with a single node containing intranodal 
microscopic deposits of tumor, preferably in a low 
tracheobronchial angle node. Multiple affected 
nodal sites have been found to carry a worse prog- 
nosis than a single affected nodal site, reducing 
survival by about 50%. 12 Matted nodes with extra- 
nodal involvement have generally not been suitable 
for resection and represent yet another group in this 
category. In a randomized prospective study, all of 
these factors would obviously need to be taken into 
account and reflected by proper stratification. 
In our study, all patients with positive ipsilateral 
mediastinal nodes were entered into this study. In 
most patients (27/40), only a single nodal station was 
affected. It was diflficult o determine retrospectively 
which of these patients would have been classified as 
in the favorable subset of patients with N2 nodes. To 
the best of out knowledge, roughly 75% would have 
been in the unfavorable category and therefore not 
subjected to operation. A preponderance of patients 
with favorable, single node involvement would ob- 
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Table IV. Comparison of various resectability rates with various neoadjuvant regimens 
Explored Resection Complete 
Entered 
Study Regimen (N) N % N % N % 
MSKCC MVP 136 114 84 89 65 
CALGB 8935 P, Vbl; post XRT  74 63 88 46 62 23 31 
+ P, Vbl 
RUSH Chemotherapy 128 (78%) 102 77 99 77 99 77 
MGH* Accelerated XRT; 40 35 88 35 88 31 78 
P, 5FU, Vbl 
MSKCC, Memorial Sloan Kettering Cancer Center; MVP, mitomycin, vinblastine, platinum; P, platinum; Vb/, vinblastine; XRT, radiation therapy; CALGB 
8935, Cancer and Leukemia Group B; RUSH, Rush-Presbyterian-St. Luke's; MGH, Massachusetts General Hospital; 5FU, 5-fluorouracil. 
*This study. 
Table V. Survival comparisons of different 
neoadjuvant regimens 
Study Median (mo) 3-year (%) 5-year (%) 
MSKCC 19 - -  17 
CALGB 8935 - -  23 - -  
RUSH 22 - -  34 
MGH* 28 - -  43 
MSKCC, Memorial Sloan Kettering Cancer Center; CALGB 8935, the 
Cancer and Leukemia Group B (CALGB 8935); RUSIt, Rush-Presbyte- 
rian-St. Luke's; MGH, Massachusetts General Hospital. 
*This study. 
viously skew the results of any study of neoadjuvant 
therapy. We could not identify better survival 
among patients with single node involvement, but 
we did see a trend toward improved survival after 30 
months. 
We had previous experience with neoadjuvant 
therapy for stage III disease and chose to change 
only one parameter. 8 We previously had used the 
same chemotherapy regimen with concurrent stan- 
dard daily radiotherapy. We chose to use acceler- 
ated radiotherapy because of favorable xperience 
treating other neoplasms and the theoretic advan- 
tages. This therapy has been shown to enhance 
tumor kill in rapidly dividing tumors. It has been 
shown to improve local control and possibly improve 
survival among patients with oropharyngeal can- 
cerJ 3 It also reduces the number of visits to the 
hospital in general, improving patient compliance. It
has been reported to increase the incidence of 
esophagitis, but in our experience this side effect was 
only moderate. The overall impact of the acceler- 
ated radiotherapy seemed to be an increased resect- 
ability rate and improved survival compared with 
our earlier experience and the reports of others who 
used different preoperative r gimens. 6-m 
We could find no correlation between radio- 
graphic and pathologic responses. All patients un- 
derwent exploration regardless of radiographic find- 
ings. A complete pathologic response was found in 
only two of 35 resected specimens (5.7%). This is 
somewhat lower than in other reports (Table III). 
Memorial Sloan Kettering reported a 17% complete 
pathologic response rate with only chemotherapy 
before operation, and Rush-Presbyterian-St. 
Luke's reported a 22% complete pathologic re- 
sponse with preoperative chemotherapy and concur- 
rent radiotherapy. 4' lO Of greater importance, how- 
ever, was the number of patients in our study whose 
disease was downstaged on the basis of negative 
mediastinal nodes (46%). The ability of this regimen 
to sterilize the mediastinal nodes certainly enhances 
our resectability rate and may translate into im- 
proved survival. The Memorial Sloan Kettering 
downstaging percentage was only 21% and the 
Cancer and Leukemia Group B (CALGB 8935) 
reported a downstaging figure of 22% among pa- 
tients who underwent resection. 4' 10 
The ultimate test of any neoadjuvant therapy rests 
on the survival rate. Our study is too small with only 
intermediate follow-up available to allow us to make 
definitive conclusions. It does at least seem to be in 
line with other reports for treating patients with N2 
disease (Table V). The projected overall survival of 
43% and median survival of 28 months is compara- 
ble to those seen in other studies that used preop- 
erative chemotherapy and radiotherapy 6 and some- 
what better than those seen in studies that used 
chemotherapy alone. 4' lo There was also a trend 
toward improved survival among patients with evi- 
dence of pathologic downstaging, as others have 
reported.4, 6  lo 
Roth and colleagues 7 and Rosell and colleagues s 
have both conducted randomized prospective stud- 
ies for stage IIIA NSCLC. Both groups used preop- 
erative chemotherapy lus operation versus opera- 
tion alone. Both trials treated patients with stage 
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I I IA disease, including some with T3N0 or T3N1 
disease. Both trials showed a statistically significant 
improvement in survival for the chemotherapy- 
treated groups. These two studies lend credence to 
the concept of neoadjuvant therapy for stage I I IA 
NSCLC. 
The body of work that exists regarding neoadju- 
vant therapy for stage I I IA  NSCLC serves as an 
impetus for further randomized prospective studies. 
Large numbers of patients will be required so that 
proper stratification can be done to help determine 
which patients with advanced disease are best 
treated in thJis fashion. As mentioned previously, N2 
disease is a spectrum, and it is important o define 
which subgroups benefit from this aggressive ap- 
proach. Because of the magnitude of the undertak- 
ing of such a randomized trial, the cost, and the 
importance of the project, it is important hat all of 
the pilot data be examined carefully to identify 
which regimen seems to offer the best chance for 
achieving the optimal result before committing all of 
the resources needed. There will continue to be a 
need for single-institution phase II trials to look for 
eren more promising regimens. 
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Discussion 
Dr. Joseph LoCicero (Boston, Mass.). I appreciate the 
invitation to discuss this paper. 
Congratulations to Dr. Mathisen and his colleagues on 
a carefully constructed study and, as usual, a skillful 
presentation. The manuscript that you kindly provided is 
most thoughtful. Since I received it early, out thoracic 
oncology program had an opportunity o review it, and 
some of these comments are collective. 
Patients with stage III disease are complex, and, as 
Dr. Shields tried to teach me during my training, N2 
disease is bad, but we make incremental progress with 
trials such as this one. It emphasizes the point hat 
patients with local or regional disease should not be 
managed in the community but should be investigated at
tertiary centers dedicated to improving survivorship 
through multimodal, multidisciplinary approaches. 
To underscore the depth of this problem, I performed a 
MEDLINE search and found 17,000 articles on lung 
cancer since 1966. One hundred eighty-eight articles 
specifically dealt with N2 disease, and 114 of these have 
been published since 1991. 
We obviously cannot address all of these issues today, 
but I would like to ask you a few questions. Everybody has 
slightly different criteria for performing mediastinoscopy. 
We at the Deaconess Hospital now perform mediastinos- 
copy on virtually all patients and use the CT scan only to 
guide our primary nodal targets. What are your specific 
criteria for mediastinoscopy, and do you think you have 
captured all of the patients with radiologically occult N2 
nodes? 
Many investigators, most of them members of this 
Association, have studied and published on patients with 
N2 disease. Martini and colleagues noted a negative 
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correlation between tumor size and survival. Do you have 
sufficient data from your 40 patients to confirm or refute 
this observation? 
Pearson, Patterson, and Watanabe, all in different 
publications, have noted increased survival among pa- 
tients with single-level versus multilevel N2 involvement. 
You have a number of single-station disease patients. Do 
you think that this group has a better survival? 
Faber and colleagues have noted ditficulty in c0mplet- 
ing rigorous postsurgical radiotherapy after a debilitating 
thoracotomy. Did all of your patients complete postsurgi- 
cal therapy, and have you found any long-term debility in 
those patients who did? 
Many radiation therapists do not favor split-course 
therapy, with some adjuvant therapy before operation and 
some after. For this reason, we use a preoperative neoad- 
juvant approach similar to the Southwest Oncology Group 
protocol reported by Rusch and associates. We give 56 Gy 
of standard radiation along with two concomitant cycles of 
cisplatin and etoposide, followed by resection on day 56. 
Isolated studies with this heavy-dose neoadjuvant therapy 
have predicted a 5-year survival between 28% and 50% in 
patients with completely resected isease. On the basis of 
your work, do you believe that we can now go back to the 
radiation therapists and say that there is justification for 
split-course therapy? 
Finally, an international trial is being mounted to 
evaluate adjuvant herapy after primary resection. This 
proposed study plans to include patients with stage I I IA 
disease. On the basis of our collective xperience from this 
Association and previous reports, as well as your report 
today, is this a backward step? 
Dr. Mathisen. Regarding mediastinoscopy, it is our 
policy, as is yours, to perform mediastinoscopy on virtually 
everybody. It has been out experience that we have picked 
up nodal involvement in people who by CT scan would 
have been thought o have negative nodes somewhere on 
the order of 12% to 15%. It is a policy that we institute 
uniformly almost all the time. There is a possibility that an 
occasional patient with occult nodal disease could have 
been missed by mediastinoscopy, but it is doubtful. 
In terms of tumor size, it is a small study and difficult o 
separate that out. Most of the patients were in the T2, T3 
category. Any conclusion about tumor size is difficult 
because of the size of the study. 
We have looked at the issue of single-level nodes versus 
multiple-level nodes. Dr. LoCicero received the manu- 
script on the fly, as it were, being pieced together at least 
to a point where he could read it, and one of the things I
think that was left out from at least he version he had was 
this evaluation, looking at just that question of single 
versus multiple nodes in terms of survival. There was no 
statistically significant difference in survival, but there is a 
trend toward improved survival for patients who have only 
a single-node station involved. 
With respect o the issue of therapy after operation, it
certainly is a challenge, I think, in this group of patients 
who have undergone a lot with preoperative chemother- 
apy and radiotherapy and then surgery. If we looked at 
those patients who were available for therapy--in other 
words, if we eliminate those who had died, those who were 
found to have metastases--there were 34 patients. All of 
these patients received postoperative radiotherapy. About 
25% to 30% of them had a reduction in the total amount, 
but all received a total dose of between 5100 cGy and 6000 
cGy total between preoperative and postoperative ther- 
apy. In terms of chemotherapy, there were three patients 
that had their chemotherapy held and another half dozen 
or so who had reductions in the total amount of chemo- 
therapy given afterward. By and large, however, the group 
got the planned postoperative therapy. 
It is difficult, I think, to sort out long-term disability 
from the effects of operation versus the total effect of 
chemotherapy, radiotherapy, and operation. It is my im- 
pression that this group of patients, although somewhat 
wilted by the experience, have recovered well, and, at least 
in this interim analysis of the data, we do not see any 
long-term disability directly attributable to their neoadju- 
vant therapy. 
With respect o the issue of split-course therapy, cer- 
tainly our experience suggests that it is very well tolerated. 
It is associated with low morbidity. There is evidence that 
these twice-a-day treatments have some experimental nd 
clinical benefit in terms of the overall tumor kill and local 
control, and I think our results are at least comparable to 
what others have seen with either higher doses or more 
conventional standard therapy. I think it does have a 
benefit for the patient in that it cuts down the amount of 
time spent going back and forth to the hospital. It is my 
impression in talking to the radiotherapists hat the 
patients have a very positive feeling about that. 
Regarding the trial that you have mentioned, I am not 
totally familiar with it. I believe that the door is still open 
for us to explore any number of different ideas. I do not 
think that it is necessarily true that preoperative therapy is 
better than postoperative therapy; it has never been 
subjected to any kind of analysis. Obviously patients with 
stage I and II disease have undergone operation, so I 
think therapy after resection for stage I and stage Il 
disease is a viable field for investigation. Concerning 
patients who have identifiable stage I I IA disease, this 
option may have to be looked at. Certainly some people 
who have dealt with superior sulcus tumors feel strongly 
that resection followed by radiotherapy might be better 
than the conventional preoperative treatment. Again, I 
think it is something we need to keep an open mind about. 
I do not think that the evidence that we have so rar is so 
conclusive that it eliminates any approaches from consid- 
eration at this point. 
Dr. Willard A. Fry (Evanston, Ill.). I think that when a 
report comes out like this from a famous institution, 
people in the community may take this as standard of 
care, whereas this is just another well-presented phase II 
trial. I urge this audience to pay attention to some of the 
comments that Valerie Rusch has made. We have five 
major cooperative groups, and at least four of those have 
agreed that they will not have competing protocols. I think 
that if you feel strongly that you have a hot idea, you 
should present it to the group and work it out so that we 
can get some significant numbers. I am afraid that some 
doctors are going to make some great conclusions on the 
basis of 40 patients in a phase II trial, and I urge the 
assembly here to give serious consideration to supporting 
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the four clinical trial groups that have agreed to have no 
competing protocols. 
Dr. Mathisen. I think your comments are absolutely 
appropriate. I think that it is important that the situation 
be carefully looked at when investing the time, effort, 
energy, and resources in a study such as you referred to in 
a multiinstitutional, multicooperative group so that the 
best regimen available is examined. I therefore agree with 
what you say about the need for that type of study. 
Because of the length of time it will take for that study to 
be completed, however, I think the door remains open for 
single-institution phase II studies to look for even more 
effective therapies, so that this hiatus from the inception 
of a randomized prospective trial is not a void of activity. 
This is a very challenging and difficult problem, and I'm 
certain that there are going to be even better solutions 
than what we currently have now, and I think those will 
come to light by single-institution Phase II trials. 
Dr. Jaek A. Roth (Houston, Texas). I think this is an 
interesting study and a well-presented series of patients. 
A year ago two groups, our group and a group from 
Barcelona, presented what I believe are the only random- 
ized studies looking at perioperative chemotherapy in
NSCLC. These studies howed that the addition of three 
eycles of chemotherapy before and three after operation 
improved survival for patients with resectable stage I I IA 
disease. I think this study provides further evidenee of that 
and emphasizes that surgery alone is no longer standard 
treatment for patients with clinically evident reseetable 
stage I I IA lung cancer. In fact, long-term survival in your 
study is virtually identical to that of the patients in our 
study who received chemotherapy alone. 
The total dose of chemotherapy in your study seems 
low, and I wonder if you had any explanation for the 
rather surprising systemie ß~cacy for this dose. Seeond, 
your treatment-related morbidity and mortality rates are 
high compared with those in other studies. You had a 10% 
treatment-related mortality rate. Perhaps the preopera- 
tive radiation therapy is actually contributing to this. Why 
not give a continuous course of radiation after operation 
only to patients with histologically positive margins? 
Dr. Mathisen. With respect o the chemotherapy, we 
decided to ehange only one variable. We had previously 
looked at ehemotherapy and radiotherapy, and we de- 
cided to continue with the same chemotherapy regimen 
and change only the radiotherapy. That was the reason for 
the selection of the chemotherapy doses. 
Regarding the treatment-related morbidity and mortal- 
ity rates, the 10% treatment-related death rate that you 
referred to was one patient who died before operation and 
two patients who died after operation (7.5%). I think 
these figures are not too dissimilar from those others have 
reported. It was ditfieult for me to identify any factors 
related to the treatment that caused these patients' death. 
Of the two who died after operation, one had pneumonia 
after a chest wall resection and the other had an arrhyth- 
mia and probably a pulmonary embolus, also after a chest 
wall resection. I therefore cannot specifically say that 
these deaths were direetly related to the treatment. 
Dr. William H. Warren (Chicago, [ll.). I wonder ifyou can 
comment on how you would now choose to cover your right 
main stem bronchial stump. We have had some ditIiculty 
with the supports that you have suggested hefe. We have 
started to use serratus anterior muscle to cover the stump as 
a broad muscle flap. Have you had an experience with that? 
Dr. Mathisen. We have not, except in highly selected 
cases. It is my feeling, orte shared by at least the majority 
of people who work at Massaehusetts General, that with 
preoperative radiotherapy atleast posing the potential for 
an increased incidenee of bronchial stump problems op- 
eration we prefer to cover it with a pedicled intercostal 
muscle. As you saw, about half of the patients had that 
done. The pericardial rat pad was used about 40% of the 
time. I think that the important message is that it is 
important to eover the stump with something. We sew all 
of our sturnps and then cover them, preferably with either 
rat pads or intercostal muscles. We have had good success, 
with no fistulas of which I am aware in nearly 75 patients 
in the two studies looking at preoperative chemotherapy 
and radiotherapy followed by surgery. I think how the 
closure is done and providing coverage with viable tissue 
is important to avoid such complications. 
